Mineralys Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview

Mineralys Therapeutics

09/11/2024 24:37

* Mineralys Therapeutics Inc  MLYS.OQ   MLYS.O  is expected
to show no change in quarterly revenue when it reports 
results on November 11 for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Mineralys Therapeutics
Inc is
for a loss of 83 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mineralys
Therapeutics Inc is $31.00​, above​ its last closing price
of $14.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.70       -0.70      -0.83     Missed  -18.6
 Jan. 1 2024   -0.61       -0.67      -0.70     Missed  -4.8
 Dec. 31 2023              -0.82      -0.61     Beat    26.1​
 Sep. 30 2023  -0.70       -0.76      -0.57     Beat    25
 ​​Jun.        -0.67       -0.72      -0.31     Beat    56.9
 30 2023                                                
 Mar. 31 2023  -0.88       -0.89      -0.51     Beat    42.7​
 Dec. 31 2022  -1.72       -1.72      -1.74     Missed  -1.2
 This summary was machine generated November 9 at 00:37 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)